| 6.42 0.12 (1.9%) | 07-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.3 | 1-year : | 9.69 |
| Resists | First : | 7.11 | Second : | 8.3 |
| Pivot price | 6.23 |
|||
| Supports | First : | 6.22 |
Second : | 5.67 |
| MAs | MA(5) : | 6.25 |
MA(20) : | 6.26 |
| MA(100) : | 4.92 |
MA(250) : | 4.4 |
|
| MACD | MACD : | 0.1 |
Signal : | 0.1  |
| %K %D | K(14,3) : | 61.1 |
D(3) : | 53.5 |
| RSI | RSI(14): 58.6 |
|||
| 52-week | High : | 7.11 | Low : | 2.36 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ACHV ] has closed below upper band by 14.9%. Bollinger Bands are 67.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.46 - 6.49 | 6.49 - 6.52 |
| Low: | 5.99 - 6.01 | 6.01 - 6.04 |
| Close: | 6.37 - 6.41 | 6.41 - 6.46 |
Achieve Life Sciences, Inc. operates as a clinical-stage pharmaceutical firm, concentrating on the development and market introduction of cytisinicline. This compound is aimed at assisting with smoking cessation and nicotine dependence, with commercial activities spanning Canada, the United States, and the United Kingdom. Cytisinicline is a naturally occurring alkaloid, which functions by engaging with nicotine receptors in the brain to lessen the intensity of nicotine withdrawal symptoms. The company holds licensing agreements with Sopharma AD and the University of Bristol. Its corporate headquarters are located in Vancouver, Canada.
Sun, 02 Aug 2026
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Sat, 01 Aug 2026
BlackRock, Inc. Expands Stake in Achieve Life Sciences (ACHV) wi - GuruFocus
Fri, 31 Jul 2026
Six New Employees Receive Achieve Stock Awards Over Four Years - Stock Titan
Fri, 31 Jul 2026
Achieve Life Sciences Announced Granting of New Hire Inducement Awards - GlobeNewswire
Thu, 30 Jul 2026
Achieve Life Sciences (ACHV) Expected to Post Earnings on Thursday - MarketBeat
Wed, 29 Jul 2026
Achieve Life Sciences (NASDAQ: ACHV) grants options and RSUs to director - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 103 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 64.2 (%) |
| Shares Short | 14,730 (K) |
| Shares Short P.Month | 8,230 (K) |
| EPS | -1.08 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.2 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -108.5 % |
| Return on Equity (ttm) | -496.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -45 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -6 |
| PEG Ratio | 17.6 |
| Price to Book value | 32.09 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|